BioHarvest Sciences Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Zaki Rakib
- Full Time Employees
- 89
- Sector
- Industrials
- Industry
- Agricultural - Commodities/Milling
- Address
- 1140-625 Howe Street Vancouver BC Canada V6C 2T6
- IPO Date
- Jan 8, 2021
- CIK
- 0001723464
- Website
- bioharvest.com
- Similar Companies
- Business
- BioHarvest Sciences Inc. operates as a biotechnology company specializing in botanical synthesis technology. The company develops and owns a patented bio-cell growth platform that produces plant-based compounds without the need to grow the underlying plants. Its core products and services span two main verticals: nutraceutical health and wellness products, including dietary supplements such as the VINIA red grape cell product containing polyphenols like Piceid resveratrol, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) targeting specific medical indications. Additionally, BioHarvest offers contract development and manufacturing services for clients seeking novel plant-based molecules. The company’s botanical synthesis platform enables large-scale, consistent production of plant metabolites with a lower environmental footprint compared to traditional agriculture and extraction methods. BioHarvest operates primarily in the United States and Israel, with headquarters in Vancouver, Canada, and was founded in 2007. Recently, BioHarvest Sciences has expanded its U.S. market presence with the launch of VINIA Blood Flow Hydration™, the first hydration product leveraging the blood flow benefits of VINIA’s Piceid resveratrol within the $13 billion U.S. electrolyte drink market. The company announced an upsized public offering raising approximately $19.9 million in gross proceeds to strengthen its balance sheet and support growth initiatives. In late 2024, BioHarvest entered a strategic partnership with Tate & Lyle PLC to develop next-generation plant-based ingredient solutions for food and beverages, reflecting a broader strategic focus on sustainable, clinically validated botanical products. Operationally, the company is advancing new botanical compositions based on plant cells from sources such as olives and pomegranates to further expand its nutraceutical and pharmaceutical pipeline. The company strictly adheres to high regulatory and quality standards including ISO and GMP certifications to support scientific and clinical rigor in its products and services. BioHarvest Sciences serves an evolving global market of health-conscious consumers and pharmaceutical clients seeking innovative, plant-based therapeutic solutions that are sustainably sourced and scientifically validated.
Company News
BioHarvest Sciences launches buyback of up to 5% of shares
BioHarvest Sciences Announces Share Repurchase Program
BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product
BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Fiinu shares jump over 6% as Conister Bank platform enters production
BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing
BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript
BioHarvest Sciences Q2 Earnings Call Highlights
BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound
BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
Head-To-Head Analysis: BioHarvest Sciences (NASDAQ:BHST) versus Nu Skin Enterprises (NYSE:NUS)
BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference
BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026
BioHarvest lands $1.4M grant for AI-driven plant science
BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
BioHarvest Sciences to Present at the 2026 BIO International Convention